Loading stock data…
Entera Bio Ltd (ENTX)
$2.84-0.17 (-5.65%)
Pre-Market$2.71-0.13 (-4.57%)· Last close Sep 9
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entera Bio Ltd. in the Healthcare sector is trading at $2.84 with a market capitalization of $58M. Wall Street consensus targets $9.00 (1 analysts), implying a +216.9% move over the next 12 months. The stock is currently 32% below its 52-week high of $4.20, remaining 62.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +216.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $42,000 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$3.54M↓ | -$3.04M↑ | -$3.26M↓ | -$2.67M↓ | -$2.56M |
| Net Income | -$3.50M↓ | -$3.02M↑ | -$3.20M↓ | -$2.66M↓ | -$2.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.81%
Volume
Today's trading volume
622,036
Recent News
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
Entera Bio (NASDAQ:ENTX) plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a discussion hosted by Can
Entera Bio shares slip as Q2 loss comes in wider than expected
Entera Bio Ltd. (NASDAQ:ENTX) shares fell 1.
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.